Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | IL6 | P05231 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | GLUL | P15104 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL12396679 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL14420691 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL6566835 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL4449434 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL11413677 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL13044469 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2597917 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL765329 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL29264693 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230028248-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | ZHEJIANG SHENZHOU PHARMACEUTICAL COMPANY LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4116314-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | Zhejiang Shenzhou Pharmaceutical Company Limited (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20210052606-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10857161-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | BODOR LABORATORIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | TAMARKIN PHARMACEUTICALS (IL) | 2007-10-25 | — | — | US | disclosed |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | TAMARKIN PHARMACEUTICALS (IL) | 2007-10-25 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142342-A1 | Pharmaceutical compounds | CYP11B2, CYP11B1, CYP2S1 | NR3C1 67/4885HIF1A 2241/4885HSD17B10 126/4885 |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | HSD3B1, HSD3B2, HSD11B1 | NR3C1 37/4885HIF1A 1047/4885HSD17B10 206/4885 |
| US-20230028248-A1 | METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONE | HSD17B2, HSD11B1, CYP17A1 | NR3C1 71/4885HIF1A 2900/4885HSD17B10 28/4885 |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | HSD3B1, HSD11B1, EBP | NR3C1 5/4885HIF1A 1372/4885HSD17B10 180/4885 |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885HIF1A 474/4885HSD17B10 359/4885 |
| US-20210052606-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885HIF1A 1095/4885HSD17B10 245/4885 |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885HIF1A 474/4885HSD17B10 359/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NR3C1 10/4885HIF1A 280/4885HSD17B10 430/4885 |
| US-10857161-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKB2, NFKBIA, NFKB1 | NR3C1 12/4885HIF1A 995/4885HSD17B10 327/4885 |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | CYP24A1, VDR, CYP2R1 | NR3C1 114/4885HIF1A 3550/4885HSD17B10 37/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885HIF1A 1095/4885HSD17B10 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.